British Journal of Cancer - Table of Contents alert Volume 106 Issue 4

TABLE OF CONTENTS Volume 106, Issue 4 (617-792) Published online 14 February 2012 In this issue Editorial Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Corrigenda Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer publishes high quality original papers and reviews that make a significant contribution to increasing understanding of the causes of cancer and to improving the treatment and survival of patients. Visit the journal online at www.bjcancer.com to view the latest research and access selected articles FREE of charge.   Editorial Top Second-line treatment for renal cell cancer G Di Lorenzo, S De Placido and C Buonerba Br J Cancer 2012 106: 617-618; 10.1038/bjc.2011.611 Full Text Minireview Top Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? N Tunariu, S B Kaye and N M deSouza Br J Cancer 2012 106: 619-628; advance online publication, January 26, 2012; 10.1038/bjc.2011.579 Abstract | Full Text Clinical Studies Top Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group A du Bois, I Vergote, P Wimberger, I Ray-Coquard, P Harter, L B Curtis and I Mitrica Br J Cancer 2012 106: 629-632; advance online publication, January 12, 2012; 10.1038/bjc.2011.608 Abstract | Full Text CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial J Alexandre, C Brown, D Coeffic, N Raban, J Pfisterer, J Mäenpää, H Chalchal, B Fitzharris, B Volgger, I Vergote, C Pisano, A Ferrero and E Pujade-Lauraine Br J Cancer 2012 106: 633-637; advance online publication, January 12, 2012; 10.1038/bjc.2011.593 Abstract | Full Text Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer M T King, R Viney, D P Smith, I Hossain, D Street, E Savage, S Fowler, M P Berry, M Stockler, P Cozzi, P Stricker, J Ward and B K Armstrong Br J Cancer 2012 106: 638-645; advance online publication, January 24, 2012; 10.1038/bjc.2011.552 Abstract | Full Text Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma D Cella, A G Bushmakin, J C Cappelleri, C Charbonneau, M D Michaelson and R J Motzer Br J Cancer 2012 106: 646-650; advance online publication, January 12, 2012; 10.1038/bjc.2011.589 Abstract | Full Text Internet chemotherapy information: impact on patients and health professionals E Davies and K-W Yeoh Br J Cancer 2012 106: 651-657; advance online publication, January 19, 2012; 10.1038/bjc.2011.601 Abstract | Full Text Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST) C Boni, M Tiseo, L Boni, E Baldini, F Recchia, C Barone, F Grossi, D Germano, E Matano, G Marini, R Labianca, F Di Costanzo, A Bagnulo, C Pennucci, C Caroti, M Mencoboni, F Zanelli, T Prochilo, M A Cafferata and A Ardizzoni on behalf of Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) Investigators Br J Cancer 2012 106: 658-665; advance online publication, January 12, 2012; 10.1038/bjc.2011.606 Abstract | Full Text Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients T Doi, H Takiuchi, A Ohtsu, N Fuse, M Goto, M Yoshida, N Dote, Y Kuze, F Jinno, M Fujimoto, T Takubo, N Nakayama and R Tsutsumi Br J Cancer 2012 106: 666-672; advance online publication, January 12, 2012; 10.1038/bjc.2011.590 Abstract | Full Text Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2 E Brain, N Isambert, F Dalenc, V Diéras, J Bonneterre, K Rezai, M Jimenez, F Mefti-Lacheraf, E Cottura, P Tresca, L Vanlemmens, C Mahier-Aït Oukhatar, F Lokiec and P Fumoleau Br J Cancer 2012 106: 673-677; advance online publication, January 12, 2012; 10.1038/bjc.2011.591 Abstract | Full Text A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours U Lassen, D L Nielsen, M Sørensen, L Winstedt, T Niskanen, Y Stenberg, S Pakola, J-M Stassen and S Glazer Br J Cancer 2012 106: 678-684; advance online publication, January 24, 2012; 10.1038/bjc.2011.609 Abstract | Full Text Translational Therapeutics Top The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis J Follet, L Corcos, G Baffet, F Ezan, F Morel, B Simon and C Le Jossic-Corcos Br J Cancer 2012 106: 685-692; advance online publication, January 31, 2012; 10.1038/bjc.2012.6 Abstract | Full Text Sigma-2 ligands induce tumour cell death by multiple signalling pathways C Zeng, J Rothfuss, J Zhang, W Chu, S Vangveravong, Z Tu, F Pan, K C Chang, R Hotchkiss and R H Mach Br J Cancer 2012 106: 693-701; advance online publication, January 17, 2012; 10.1038/bjc.2011.602 Abstract | Full Text Molecular Diagnostics Top The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma S Dutta, J J Going, A B C Crumley, Z Mohammed, C Orange, J Edwards, G M Fullarton, P G Horgan and D C McMillan Br J Cancer 2012 106: 702-710; advance online publication, January 12, 2012; 10.1038/bjc.2011.610 Abstract | Full Text The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells M J Nyhan, T R O'Donovan, B Elzinga, L C Crowley, G C O'Sullivan and S L McKenna Br J Cancer 2012 106: 711-718; advance online publication, January 12, 2012; 10.1038/bjc.2011.604 Abstract | Full Text Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer T Ettl, K Baader, C Stiegler, M Müller, A Agaimy, J Zenk, T Kühnel, M Gosau, K Zeitler, S Schwarz and G Brockhoff Br J Cancer 2012 106: 719-726; advance online publication, January 12, 2012; 10.1038/bjc.2011.605 Abstract | Full Text FGFR2 gene amplification and clinicopathological features in gastric cancer K Matsumoto, T Arao, T Hamaguchi, Y Shimada, K Kato, I Oda, H Taniguchi, F Koizumi, K Yanagihara, H Sasaki, K Nishio and Y Yamada Br J Cancer 2012 106: 727-732; advance online publication, January 12, 2012; 10.1038/bjc.2011.603 Abstract | Full Text Serum biomarker panels for the diagnosis of gastric adenocarcinoma H S Ahn, Y S Shin, P J Park, K N Kang, Y Kim, H-J Lee, H-K Yang and C W Kim Br J Cancer 2012 106: 733-739; advance online publication, January 12, 2012; 10.1038/bjc.2011.592 Abstract | Full Text Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma H Konishi, D Ichikawa, S Komatsu, A Shiozaki, M Tsujiura, H Takeshita, R Morimura, H Nagata, T Arita, T Kawaguchi, S Hirashima, H Fujiwara, K Okamoto and E Otsuji Br J Cancer 2012 106: 740-747; advance online publication, January 19, 2012; 10.1038/bjc.2011.588 Abstract | Full Text Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer E Dotan, N J Meropol, F Zhu, F Zambito, B Bove, K Q Cai, A K Godwin, E A Golemis, I Astsaturov and S J Cohen Br J Cancer 2012 106: 748-755; advance online publication, January 12, 2012; 10.1038/bjc.2011.587 Abstract | Full Text Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients M P Myklebust, Ø Fluge, H Immervoll, A Skarstein, L Balteskard, O Bruland and O Dahl Br J Cancer 2012 106: 756-762; 10.1038/bjc.2011.548 Abstract | Full Text Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells J Tanizaki, I Okamoto, K Takezawa, K Sakai, K Azuma, K Kuwata, H Yamaguchi, E Hatashita, K Nishio, P A Janne and K Nakagawa Br J Cancer 2012 106: 763-767; advance online publication, January 12, 2012; 10.1038/bjc.2011.586 Abstract | Full Text Changes in circulating microRNA levels associated with prostate cancer R J Bryant, T Pawlowski, J W F Catto, G Marsden, R L Vessella, B Rhees, C Kuslich, T Visakorpi and F C Hamdy Br J Cancer 2012 106: 768-774; advance online publication, January 12, 2012; 10.1038/bjc.2011.595 Abstract | Full Text Genetics and Genomics Top Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women L Sidon, S Ingham, T Clancy, R Clayton, A Clarke, E A Jones, F Lalloo and D G R Evans Br J Cancer 2012 106: 775-779; advance online publication, December 20, 2011; 10.1038/bjc.2011.573 Abstract | Full Text Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis F Cardinale, P Bruzzi and C Bolognesi Br J Cancer 2012 106: 780-790; advance online publication, December 20, 2011; 10.1038/bjc.2011.567 Abstract | Full Text Corrigenda Top Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours M A Rijlaarsdam, H A D M van Herk, A J M Gillis, H Stoop, G Jenster, J Martens, G J L H van Leenders, W Dinjens, A M Hoogland, M Timmermans and L H J Looijenga Br J Cancer 2012 106: 791; 10.1038/bjc.2012.37 Full Text Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer E C M Zeestraten, M Maak, M Shibayama, T Schuster, U Nitsche, T Matsushima, S Nakayama, K Gohda, H Friess, C J H van de Velde, H Ishihara, R Rosenberg, P J K Kuppen and K-P Janssen Br J Cancer 2012 106: 792; 10.1038/bjc.2012.38 Full Text Advertisement Ensure your access to British Journal of Cancer If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now at http://www.nature.com/librec/svc/request/makeCommRequest?id=2.   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.